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SRJ09, a promising anticancer drug lead: elucidation of mechanisms of 
antiproliferative and apoptogenic effects and assessment of in vivo antitumor efficacy 
ABSTRACT 
SRJ09 (3,19-(2-bromobenzylidene)andrographolide), a semisynthetic andrographolide (AGP) 
derivative, was shown to induce G1 cell cycle arrest and eventually apoptosis in breast and 
colon cancer cell lines. The present investigation was carried out to elucidate the mechanisms 
cell cycle arrest and apoptosis and evaluate the in vivo antitumor activity of SRJ09. The in 
vitro growth inhibitory properties of compounds were assessed in colon (HCT-116) and 
breast (MCF-7) cancer cell lines. Immunoblotting was utilized to quantitate the protein levels 
in cells. The gene expressions were determined using reverse transcriptase PCR (RT-PCR). 
Pharmacokinetic investigation was carried out by determining SRJ09 levels in plasma of 
Balb/C mice using HPLC. In vivo antitumor activity was evaluated in athymic mice carrying 
HCT-116 colon tumor xenografts. SRJ09 displayed improved in vitro activity when 
compared with AGP by producing rapid cell killing effect in vitro. Its activity was not 
compromised in MES-SA/Dx5 multidrug resistant (MDR) cells expressing p-glycoprotein. 
Cells treated with SRJ09 (0.1⿿10 μM) displayed increased p21 protein level, which 
corresponded with gene expression. Whereas CDK4 protein level and gene expression was 
suppressed. The treatment did not affect cyclin D1. Changes of these proteins paralleled G1 
cell cycle arrest in both cell lines as determined by flow cytometry. Induction of apoptosis by 
SRJ09 in HCT-116 cells which occurred independent of p53 and bcl-2 was inhibited in the 
presence of caspase 8 inhibitor, implicating the extrinsic apoptotic pathway. A single dose 
(100 mg/kg, i.p) of SRJ09 produced a plasma concentration range of 12⿿30.4 μM. At 
400 mg/kg (q4dX3), it significantly retarded growth of tumor xenografts. The antitumor 
activity of SRJ09 is suggested mediated via the induction of p21 expression and suppression 
of CDK-4 expression without affecting cyclin D1 to trigger G1 arrest leading to apoptosis. 
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